TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2

Recruiting

• Conditions: COVID-19; SARS-CoV-2; 10047438

• Registration Number: NL-OMON52215
• Lead Sponsor: Amsterdam UMC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 1000

Inclusion Criteria

- All patients that are treated with neutralizing SARS-CoV-2 antibodies and
other antivirals against or as prevention of SARS-CoV-2 as standard of care.
- Patients have to be aged >= 18 y.

Exclusion Criteria

- No informed consent is provided by the patient
- Patients not suitable to fulfil study procedures

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- A. What are the SARS-CoV-2 viral load kinetics during and after treatment<br /><br>with neutralizing monoclonal antibodies and other antiviral agents against<br /><br>SARS-CoV-2?<br /><br>- B. What is the risk of SARS-CoV-2 infection after prophylactic use of<br /><br>monoclonal antibodies or other antiviral agents?<br /><br>- C. Do viral variants, spike mutations and immune escape occur during<br /><br>treatment with neutralizing monoclonal antibodies and other antiviral agents<br /><br>against SARS-CoV-2?<br /><br>- D. What are the viral antibody and inflammatory response kinetics during and<br /><br>after treatment with neutralizing monoclonal antibodies and other antiviral<br /><br>agents against SARS-CoV-2?</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Not-applicable</p><br>